Chandra Bhagat

Who are the top shareholders of the Chandra Bhagat?

The top shareholders of Chandra Bhagat include Hemant Chandravadan Bhagat with 35.5%, Team Anamika Algo Limited at 9.5%, and individual investors holding 11.16%. There are no pledged promoter holdings or mutual funds invested in the company.

The top shareholders of Chandra Bhagat include the promoters, with Hemant Chandravadan Bhagat holding the largest share at 35.5%. The highest public shareholder is Team Anamika Algo Limited, which owns 9.5%. Additionally, individual investors collectively hold 11.16% of the shares. There is also one foreign institutional investor (FII) that holds 0.61% of the company's shares. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

how big is Chandra Bhagat?

As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, classifying it as a Micro Cap company. There is no available financial data for the latest four quarters, but as of March 2024, Shareholder's Funds are valued at 29.01 Cr, with Total Assets of 101.78 Cr.

Market Cap: As of Jun 05, Chandra Bhagat Pharma Ltd has a market capitalization of 46.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid Consolidated or Standalone financial data available for the latest four quarters, including figures for Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the reporting period of March 2024. The Shareholder's Funds are valued at 29.01 Cr, and the Total Assets amount to 101.78 Cr.

Who are in the management team of Chandra Bhagat?

As of March 2021, the management team of Chandra Bhagat includes Hemant C Bhagat (Chairman & Managing Director), Pranav H Bhagat (Whole-time Director), Prachi Pranav Bhagat (Director & CFO), Ravindra Gajanan Awati (Independent Director), and Abha Praveen Doshi (Independent Director). They are responsible for the company's governance and strategic direction.

As of March 2021, the management team of Chandra Bhagat includes the following individuals:<BR><BR>1. Hemant C Bhagat - Chairman & Managing Director<BR>2. Pranav H Bhagat - Whole-time Director<BR>3. Prachi Pranav Bhagat - Director & CFO<BR>4. Ravindra Gajanan Awati - Independent Director<BR>5. Abha Praveen Doshi - Independent Director<BR><BR>These members play key roles in the governance and strategic direction of the company.

What does Chandra Bhagat do?

Chandra Bhagat Pharma Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2003 and converted to a Public Limited Company in 2019. It currently has no reported sales or profit data, with a market cap of Rs 46 Cr and a P/E ratio of 42.00.

Overview:<BR>Chandra Bhagat Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated in 2003 as "Chandra Bhagat Pharma Private Limited" and later converted to a Public Limited Company, changing its name to "Chandra Bhagat Pharma Limited" on March 20, 2019. There is no sales or profit data reported for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: Rs 46 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 42.00<BR>Industry P/E: 28<BR>Dividend Yield: 0.00%<BR>Debt Equity: 0.40<BR>Return on Equity: 3.03%<BR>Price to Book: 1.64<BR><BR>Contact Details:<BR>Address: Not available<BR>Phone: Not available<BR>Email: Not available<BR>Website: Not available

When is the next results date for Chandra Bhagat?

No Upcoming Board Meetings

Has Chandra Bhagat declared dividend?

No Dividend History Available

Who are the peers of the Chandra Bhagat?

Chandra Bhagat's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, Chandra Bhagat has below average growth and a 1-year return of -42.15%.

Peers: The peers of Chandra Bhagat are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Vista Pharma., Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest have below average management risk. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is found at Divi's Lab., Torrent Pharma, Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio. Excellent capital structure is noted at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while good capital structure is seen at Torrent Pharma, and below average capital structure is present at Divi's Lab., Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Vista Pharma. has the lowest at -23.81%. Chandra Bhagat's 1-year return is -42.15%, which is significantly lower than both. Additionally, the six-month return is negative for Vista Pharma., Chandra Bhagat, Guj. Terce Labs., ANG Lifesciences, and Shree Ganesh Bio.

Is Chandra Bhagat overvalued or undervalued?

As of May 30, 2025, Chandra Bhagat's valuation has been downgraded to risky due to overvaluation, with a PE ratio of 42.25 and an EV to EBITDA of -36.70, significantly underperforming its peers and the market.

As of 30 May 2025, the valuation grade for Chandra Bhagat has moved from does not qualify to risky, indicating a significant downgrade in its investment attractiveness. The company is currently considered overvalued, especially when compared to its peers. Key ratios include a PE ratio of 42.25, an EV to EBITDA of -36.70, and a ROE of 3.03%. <BR><BR>In comparison, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla Ltd. shows a more favorable PE of 22.99 and an EV to EBITDA of 15.93, both suggesting better valuation metrics. Additionally, Chandra Bhagat's stock has underperformed significantly, with a year-to-date return of -15.15% compared to a 5.58% return for the Sensex, reinforcing the notion that the stock is overvalued in its current state.

What is the technical trend for Chandra Bhagat?

As of June 4, 2025, Chandra Bhagat's technical trend is mildly bearish, with conflicting signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, while daily moving averages also suggest caution.

As of 4 June 2025, the technical trend for Chandra Bhagat has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The Bollinger Bands and KST are both mildly bearish on the weekly and monthly time frames. The moving averages on the daily chart are bearish, which adds to the overall cautious outlook. The Dow Theory shows a mildly bullish signal on the weekly but is bearish on the monthly. The On-Balance Volume (OBV) is mildly bullish on both weekly and monthly charts, suggesting some accumulation. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

How has been the historical performance of Chandra Bhagat?

Chandra Bhagat's historical performance shows significant declines in net sales and profits from March 2024 to March 2025, with net sales dropping from 221.37 Cr to 86.72 Cr and increasing debt levels from 16.43 Cr to 20.86 Cr, indicating a challenging financial environment.

Answer:<BR>The historical performance of Chandra Bhagat shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Chandra Bhagat's net sales peaked at 221.37 Cr in March 2024 but dropped to 86.72 Cr by March 2025. The total operating income followed a similar trend, decreasing from 221.37 Cr in March 2024 to 86.72 Cr in March 2025. The total expenditure also saw a decline, from 228.42 Cr in March 2024 to 88.18 Cr in March 2025. Operating profit (PBDIT) was negative in both March 2025 and March 2024, at -1.46 Cr and -7.05 Cr respectively, indicating a challenging operational environment. Profit before tax showed a slight decrease from 2.26 Cr in March 2024 to 1.17 Cr in March 2025, while profit after tax also fell from 1.53 Cr to 0.86 Cr in the same period. The company's total assets remained relatively stable, slightly decreasing from 101.78 Cr in March 2024 to 101.46 Cr in March 2025. Total debt increased from 16.43 Cr to 20.86 Cr, reflecting a rise in financial obligations. Cash flow from operating activities was consistent, with 6.00 Cr in March 2024 and 5.00 Cr in March 2023, but the net cash flow turned negative in March 2024 at -1.00 Cr. Overall, Chandra Bhagat's financial performance indicates a decline in sales and profits, alongside increasing debt levels, suggesting a need for strategic adjustments.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 17-Mar, Chandra Bhagat Pharma Ltd's stock price is currently at Rs. 34.50, showing a short-term increase despite significant declines over the past month and year. The stock is underperforming in the long term, trading below moving averages and experiencing reduced investor participation.

As of 17-Mar, Chandra Bhagat Pharma Ltd's stock price is rising, currently at Rs. 34.50, reflecting a change of 1.47 (4.45%) upward. This increase comes despite the stock's recent performance, which has shown significant declines over various periods, including a 1-month drop of 18.25% and a 1-year decrease of 44.89%. <BR><BR>Today's trading session saw the stock open with a loss of 4.63%, hitting a new 52-week low of Rs. 31.45 before recovering to its current price. The stock outperformed its sector by 4.17% today, indicating a relative strength compared to its peers. However, it is important to note that the stock has been trading below its moving averages across multiple time frames, suggesting a longer-term downward trend. Additionally, there has been a notable decline in investor participation, with delivery volume falling by 65.28% against the 5-day average.<BR><BR>In summary, while the stock is experiencing a short-term rise today, it is still facing significant challenges in terms of overall performance and investor interest.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 18-Mar, Chandra Bhagat Pharma Ltd's stock price is stable at Rs. 34.50 but has seen significant declines, including a 44.89% drop over the past year and a 69.14% decrease over three years. The stock's recent performance, including hitting a new 52-week low, reflects negative investor sentiment and a bearish trend.

As of 18-Mar, Chandra Bhagat Pharma Ltd's stock price is currently stable at Rs. 34.50, showing no change from the previous trading session. However, the stock has been experiencing a significant decline over various periods. Over the past week, it has decreased by 0.75%, and in the last month, it has fallen by 13.97%. Year-to-date, the stock is down 16.36%, and over the past year, it has plummeted by 44.89%. This downward trend is further highlighted by a staggering 69.14% drop over the last three years, while the benchmark Sensex has increased by 32.27% during the same period.<BR><BR>Today, the stock hit a new 52-week low of Rs. 31.45, indicating a negative sentiment among investors. The stock opened with a loss of 4.63% and reached an intraday low of Rs. 31.45, reflecting a decline of 4.78%. Although it touched an intraday high of Rs. 34.50, the overall trading pattern has been erratic, with the stock not trading on three days out of the last 20. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume dropping by 65.28% against the 5-day average, indicating a lack of confidence among traders. Overall, these factors contribute to the perception that Chandra Bhagat Pharma Ltd is experiencing a decline in its stock price.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 19-Mar, Chandra Bhagat Pharma Ltd's stock price is rising to Rs 36.00, up 4.35%, with significant investor interest reflected in a 900% increase in delivery volume. However, the stock has a year-to-date decline of 12.73% and a 44.62% drop over the past year, indicating ongoing volatility despite the recent rebound.

As of 19-Mar, Chandra Bhagat Pharma Ltd's stock price is rising, currently at Rs 36.00, reflecting a change of Rs 1.5 or 4.35%. This increase is notable as the stock has outperformed its sector by 6.5% today. The stock reached an intraday high of Rs 36, indicating positive momentum within the trading day. Additionally, there has been a significant rise in investor participation, with delivery volume on 17 March increasing by 900% compared to the 5-day average, suggesting heightened interest from investors.<BR><BR>Despite the positive movement today, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date drop of 12.73% and a staggering 44.62% decrease over the past year. However, the current performance indicates a temporary rebound, especially in light of the erratic trading patterns observed, where the stock did not trade on 3 out of the last 20 days. This volatility may contribute to the current rise in price as investors react to recent trading activity.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 20-Mar, Chandra Bhagat Pharma Ltd's stock price is rising to Rs 36.00, up 9.12%, driven by strong investor interest and a significant increase in trading volume. Despite a year-to-date decline of 12.73%, the current performance suggests a potential short-term recovery.

As of 20-Mar, Chandra Bhagat Pharma Ltd's stock price is rising, currently at Rs 36.00, reflecting a change of Rs 3.01 or 9.12%. This increase can be attributed to several factors. Firstly, the stock has outperformed its sector by 6.5% today, indicating a stronger performance relative to its peers. Additionally, the stock reached an intraday high of Rs 36, which is a 4.35% increase from previous levels.<BR><BR>Moreover, there has been a significant rise in investor participation, with delivery volume on 17 March increasing by 900% compared to the 5-day average. This surge in trading activity suggests heightened interest and confidence among investors, contributing to the upward price movement.<BR><BR>Despite this positive performance today, it is important to note that the stock has experienced a decline over longer periods, with a year-to-date drop of 12.73% and a one-year decline of 44.62%. However, the current rise in price indicates a potential short-term recovery or positive sentiment in the market for Chandra Bhagat Pharma Ltd.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 23-Mar, Chandra Bhagat Pharma Ltd's stock price has fallen to Rs. 31.45, marking a 4.67% decrease and a new 52-week low. The stock has significantly underperformed compared to the Sensex, with declines of 21.57% over the past month and 51.62% over the past year.

As of 23-Mar, Chandra Bhagat Pharma Ltd's stock price is falling, currently at Rs. 31.45, which reflects a decrease of Rs. 1.54 or 4.67%. The stock has reached a new 52-week low today, indicating a significant decline in its value. Over the past week, the stock has underperformed, with a drop of 4.78%, compared to a 3.72% decline in the benchmark Sensex. <BR><BR>In the last month, the stock has decreased by 21.57%, significantly worse than the Sensex's 12.72% decline. Year-to-date, the stock is down 23.76%, while the Sensex has only fallen 14.70%. Over the past year, the stock has plummeted by 51.62%, contrasting sharply with the Sensex's modest 5.47% decline. The three-year performance shows an even steeper decline of 67.34%, while the Sensex has gained 25.50% during the same period.<BR><BR>Today's trading activity further highlights the stock's struggles, as it opened with a gap down of 4.36% and touched an intraday low of Rs. 31.45. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a bearish trend. Additionally, the overall sector, Pharmaceuticals & Drugs, has also seen a decline of 3.58%, contributing to the negative sentiment surrounding the stock. Despite a rise in investor participation, with delivery volume increasing by 93.18% against the 5-day average, the overall performance remains weak, leading to the stock's continued fall.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 24-Mar, Chandra Bhagat Pharma Ltd's stock price is Rs. 31.45, unchanged from the previous day. The stock has seen significant declines, with a year-to-date drop of 23.76% and a one-year decline of 51.62%, indicating a bearish trend amidst broader sector losses.

As of 24-Mar, Chandra Bhagat Pharma Ltd's stock price is currently at Rs. 31.45, showing no change from the previous day. The stock has been experiencing a significant decline over various periods, with a year-to-date drop of 23.76% and a one-year decline of 51.62%. This downward trend is further highlighted by the stock hitting a new 52-week low today.<BR><BR>Today's performance indicates that the stock underperformed its sector by 1.1% and opened with a loss of 4.36%. Throughout the day, it reached an intraday high of Rs. 34.5 but also touched a low of Rs. 31.45, reflecting volatility in trading. The stock has been trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bearish trend.<BR><BR>Additionally, the broader pharmaceuticals and drugs sector has fallen by 3.58%, contributing to the negative sentiment surrounding Chandra Bhagat Pharma Ltd. Despite a rise in investor participation, with delivery volume increasing by 93.18% against the 5-day average, the overall market conditions and the stock's performance suggest a continued decline.

Why is Chandra Bhagat Pharma Ltd falling/rising?

As of 25-Mar, Chandra Bhagat Pharma Ltd's stock price is Rs. 31.45, marking a new 52-week low and a decline of 21.57% over the past month. The stock has significantly underperformed, down 23.76% year-to-date and 45.87% over the past year, amidst a negative trend in the Pharmaceuticals & Drugs sector.

As of 25-Mar, Chandra Bhagat Pharma Ltd's stock price is currently at Rs. 31.45, showing no change from the previous close. The stock has hit a new 52-week low today, indicating a significant decline in value. Over the past week, the stock has decreased by 8.84%, and it has experienced a substantial drop of 21.57% over the past month. Year-to-date, the stock is down 23.76%, and it has fallen 45.87% over the past year, significantly underperforming compared to the Sensex, which has only declined by 3.52% in the same period.<BR><BR>Today's trading performance reflects a negative trend, as the stock opened with a loss of 4.36% and reached an intraday low of Rs. 31.45, which is 4.67% lower than its previous close. Additionally, the stock has underperformed its sector by 1.1%. The moving averages indicate that Chandra Bhagat is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, further suggesting a bearish trend.<BR><BR>Despite some positive signs, such as a rise in delivery volume by 93.18% against the 5-day average, the overall sentiment remains negative due to the erratic trading patterns and the broader decline in the Pharmaceuticals & Drugs sector, which has fallen by 3.58%. Overall, these factors contribute to the stock's downward trajectory.

Which are the latest news on Chandra Bhagat?